🟢 Nurix Therapeutics Inc is trading 7.1% up today after reporting high response rates in Phase 1 leukemia trial

Nurix Therapeutics Inc is trading at $16.39 (7.1% up) after releasing updated Phase 1a/1b data for its BTK degrader bexobrutideg (NX-5948) in relapsed or refractory CLL/SLL.

• The company reported high objective response rates of up to 92.9% and durable progression-free survival with a favorable safety profile.
• The data, presented at the European Hematology Association (EHA) Congress, has significantly boosted investor optimism regarding the company's clinical pipeline and future commercial potential.